12:00 AM
Jun 09, 2014
 |  BC Week In Review  |  Clinical News  |  Clinical Status

ANG1005: Phase II started

Angiochem began an open-label, U.S. Phase II trial to evaluate ANG1005 in up to 40 patients with progressive or recurrent HER2-positive breast cancer with brain metastases. Late last month, FDA granted Orphan Drug and Fast Track designations to ANG1005 to treat glioblastoma multiforme (GBM). The product is also in Phase II testing for primary brain cancers,...

Read the full 257 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >